Eli Lilly's late-phase trials SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN show that adults with obesity maintained most of their weight loss after switching from high doses of injectable therapies Wegovy and Zepbound to either oral Foundayo or lower-dose Zepbound. Participants who continued Zepbound at maximum tolerated doses maintained all prior weight loss, while those who switched to Foundayo or reduced Zepbound doses maintained nearly all weight loss after one year. These findings highlight the potential for durable weight management using oral and injectable GLP-1 therapies, addressing the challenge of weight regain in obesity care. Both drugs showed safety profiles consistent with previous studies, supporting their use for long-term obesity treatment.
